AI-Powered Precision Medicine Market Size Worth USD 42.17 Billion By 2034 | CAGR: 38.49%

The global AI-powered precision medicine market is expected to reach USD 42.17 billion by 2034, according to a new study by Polaris Market Research. The report “AI-Powered Precision Medicine Market Size, Share, Trends, & Industry Analysis Report By Component, By Application, By Therapeutic Area, By End User, and By Region – Market Forecast, 2026–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Market expansion is being supported by the growing availability of linked genomic and clinical datasets, wider use of artificial intelligence in molecular interpretation, increasing demand for biomarker-driven treatment strategies, and the development of longitudinal approaches to disease monitoring. The market is also moving beyond standalone prediction tools. Vendors are increasingly combining genomic, clinical, imaging, pathology, and real-world data within platforms designed to support decisions across the drug-development and care continuum.

“AI-powered precision medicine is moving into a more commercially demanding phase. The question is no longer simply whether an algorithm can identify a pattern. Buyers increasingly want to know whether that insight can be validated, integrated into a workflow, connected to a measurable outcome, and reused across programs. The strongest platforms will therefore be those that combine high-quality data with clinical or research utility, rather than those competing on model performance alone." — Polaris Market Research & Consulting, Senior Life Sciences Analyst

AI-Powered Precision Medicine Market Investment Signals 2026

Investment Theme	Market Signal	Business Implication
Multimodal AI	Growing integration of genomic, clinical, imaging, and pathology data	Expands the number of decisions that can be supported by a single data platform
Population-scale genomic datasets	Increasing availability of linked genomic and EHR data	Improves opportunities for population-aware model development and validation
AI-enabled drug development	Pharmaceutical companies are investing in foundation models, biomarkers, and data partnerships	Creates new revenue opportunities beyond diagnostic software
Longitudinal molecular monitoring	Growing interest in repeated molecular measurements and MRD testing	Supports recurring testing, monitoring, and evidence-generation models
Clinical AI validation	Greater regulatory focus on model credibility and context of use	Raises the value of validation, governance, and lifecycle-management capabilities

Questions? Request a sample or make an inquiry before buying this report by clicking the link below: AI-Powered Precision Medicine Market Report

Key Factors Driving AI-Powered Precision Medicine Industry in 2026

Multimodal Data Is Becoming a Commercial Asset

Precision medicine platforms are increasingly built around datasets that combine molecular and clinical information rather than relying on a single data type. This shift is visible in the pharmaceutical sector, where Tempus, AstraZeneca, and Pathos entered expanded strategic agreements in April 2025 to develop a multimodal foundation model for oncology. The agreements included USD 200 million in data licensing and model-development fees to Tempus.

Longitudinal Monitoring Is Expanding the Role of AI

Precision medicine is gradually shifting from one-time molecular characterization toward repeated measurement. Minimal residual disease monitoring is a clear example. In July 2026, Tempus announced a definitive agreement to acquire Personalis for an enterprise value of approximately USD 1.5 billion, bringing Personalis' tumor-informed MRD technology into Tempus' multimodal data and AI platform.

Regulatory Expectations Are Moving Closer to the Model

AI adoption in drug development is also becoming more evidence-driven. In January 2025, the U.S. Food and Drug Administration issued draft guidance proposing a risk-based credibility framework for AI models used to support regulatory decisions concerning the safety, effectiveness, or quality of drugs and biological products. The framework links credibility assessment to a model's defined context of use.

AI-Powered Precision Medicine Market Report Highlights

• North America dominated the global AI-powered precision medicine market share with 41.28% in 2025. The leading share is driven by its strong genomic and clinical data infrastructure and increasing adoption of AI-enabled diagnostics and precision oncology.
• The Asia Pacific market is projected to register the highest CAGR of 42.63% during 2026–2034. The market is supported by rapid healthcare digitization and genomic testing.
• Software held the largest share of 42.18% in 2025. Rising demand for AI algorithms and clinical decision-support platforms drives the segment growth.
• Therapy selection accounted for 18.34% share in 2025. The dominance is fueled by the increasing need for personalized treatment matching and rising use of AI for treatment-response prediction and patient stratification.
• A few key players are AstraZeneca, Caris Life Sciences, Guardant Health, Illumina, Microsoft, NVIDIA, Owkin, PathAI, Personalis, QIAGEN, Recursion Pharmaceuticals, Roche (Foundation Medicine), SOPHiA GENETICS, and Tempus AI.

AI-Powered Precision Medicine Market report based on component, application, therapeutic area, end user, and region:

By Component Outlook (Revenue, USD Billion, 2021–2034)

• Software
• Hardware
• Services

By Application Outlook (Revenue, USD Billion, 2021–2034)

• Drug Discovery
• Diagnosis & Screening
• Therapy Selection
• Monitoring & Prognosis
• Clinical Trial Optimization

By Therapeutic Area Outlook (Revenue, USD Billion, 2021–2034)

• Oncology
• Neurology
• Cardiology
• Immunology
• Rare Disease

By End User Outlook (Revenue, USD Billion, 2021–2034)

• Pharma & Biotechnology
• Healthcare Providers
• Research Institutes
• Diagnostic Laboratories

By Regional Outlook (Revenue, USD Billion, 2021–2034)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Taiwan
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • South Africa
  • Rest of Middle East & Africa